In this study, the authors indicated that FXa, originating from myeloid cells, induces the immune evasion of tumors via signaling through PAR2, and FXa-specific inhibitor, rivaroxaban, shows a synergistic effect with anti-PD-L1 therapy in improving anti-tumor immunity [139]. The gene discussed is F2RL1; the disease is neoplasm.